Brief: Elicio Therapeutics Says First Patient Dosed In Phase 1/2 Study Of Lymph Node-Targeted Investigational Therapeutic Vaccine
27/04/2023 14:28
April 27 (Reuters) - Elicio Therapeutics Inc ELTX.O :
* ELICIO THERAPEUTICS ANNOUNCES FIRST PATIENT DOSED IN PHASE
1/2
STUDY OF LYMPH NODE-TARGETED INVESTIGATIONAL THERAPEUTIC VACCINE
ELI-002 7P (AMPLIFY-7P) IN KRAS/NRAS MUTATED SOLID TUMORS
Source text for Eikon: ID:nGNX2jMxnz
Further company coverage: ELTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Elicio Therapeutics
See all newsFactbox: Moderna-Merck melanoma vaccine leads race for first therapeutic cancer vaccine
Elicio Therapeutics Q2 net loss narrows as R&D expenses fall
Elicio Therapeutics Inc expected to post a loss of 54 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Datadog, Terawulf, Paychex
Elicio shares slide after pancreatic cancer vaccine falls short in mid-stage study (updated)